AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Day

Hour

Minute

Second

A Patient-Inspired Future for COPD Drug Development

9:00 am - Thursday 17th September 2026

Re-evaluating the primary endpoints in clinical trials to focus on outcomes that are more meaningful to patients’ daily lives and what they truly care about
Leverage patient-led insights and initiatives to design studies that improve adoption, engagement, and real-world impact
Capitalise on renewed industry momentum to build collaborative, patient-centric approaches that accelerate more effective COPD therapies
Hear a direct patient perspective to uncover crucial insights into shaping successful clinical trials and drug development programs

Bruce Miller

Chief Scientific Officer

COPD Foundation

Chip Kreisman

Patient Advocate

COPD Foundation